Dexcom ships G5 to Medicare beneficiaries

 - 
Friday, August 25, 2017

SAN DIEGO – Dexcom has begun shipping the Dexcom G5 to Medicare beneficiaries who meet coverage requirements for continuous glucose monitoring, according to news reports. CMS in January classified “therapeutic” CGMs as DME, paving the way for coverage if certain criteria are met. In July, Dexcom reached an agreement with Ascensia Diabetes Care to bundle Ascensia’s ContourNext One glucose monitoring system with the G5. CMS has set a one-time fee of $236 to $277 for the CGM receiver, and a monthly allowable of $248.38 for related accessories. Demand for the G5 is so high that 20,000 beneficiaries are “in the pipeline” for a device. The G5 is currently the only CGM approved for insulin dosing.